Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway

Current Alzheimer Research

Volumn 8, Issue 4, 2011, Pages 385-392

  Adwan, L I ^a   Basha, R ^a,b   Abdelrahim, M ^b   Subaiea, G M ^a   Zawia, N H ^a  

^a UNIVERSITY OF RHODE ISLAND   (United States)

^b M D ANDERSON CANCER CENTER ORLANDO   (United States)

Author keywords

Alzheimer's disease; Amyloid beta; APP; Sp1; Tolfenamic acid; Transcription

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; TOLFENAMIC ACID; TRANSCRIPTION FACTOR SP1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RECEPTOR DOWN REGULATION; TREATMENT DURATION;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTHRANILIC ACIDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; HUMANS; MICE; MICE, INBRED C57BL; RNA, MESSENGER; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSCRIPTION FACTORS;

EID: 79959334031     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720511795745285     Document Type: Article

References (46)

1. Terry RD, Gonatas NK, Weiss M. Ultrastructural studies in Alzheimer's presenile dementia. Am J Pathol 44: 269-297 (1964).
2. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science 314: 777-781 (2006).
3. Haass C, Hung AY, Selkoe DJ. Processing of beta-amyloid precursor protein in microglia and astrocytes favors an internal localization over constitutive secretion. J Neurosci 11: 3783-3793 (1991).
4. Urbanc B, Cruz L, Buldyrev SV, Havlin S, Irizarry MC, Stanley HE, et al. Dynamics of plaque formation in Alzheimer's disease. Biophys J 76: 1330-1334 (1999).
5. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 362: 329-44 (2010).
6. Shoji M, Golde TE, Ghiso J, Cheung TT, Estus S, Shaffer LM, et al. Production of the Alzheimer amyloid P3 protein by normal proteolytic processing. Science 258: 126-129 (1992).
7. Näslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283: 1571-1577 (2000).
8. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 77: 1081-1132 (1997).
9. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, et al. Intraneuronal Alzheimer Aß42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol 161: 1869-1879 (2002).
10. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM, et al. Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol 172: 1683-1692 (2008).
11. Selkoe DJ. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci 16: 403-409 (1993).
12. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356 (2002).
13. Roberson E, Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 314: 781-784 (2006).
14. Latchman D. Transcription factors as potential targets for therapeutic drugs. Curr Pharm Biotechnol 1: 57-61 (2000).
15. Cai W, Hu L, Foulkes J. Transcription-modulating drugs: mechanism and selectivity. Current Opinion in Biotechnolog 7: 608-615 (1996).
16. Docagne F, Gabriel C, Lebeurrier N, Lesné S, Hommet Y, Plawinski L, et al. Sp 1 and Smad transcription factors co-operate to mediate TGF-beta-dependent activation of amyloid-beta precursor protein gene transcription. Biochem J 383: 393-399 (2004).
17. Lukiw WJ, Rogaev EI, Wong L, Vaula G, McLachlan DR, St George Hyslop P. Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Brain Res Mol Brain Res 22: 121-131 (1994).
18. Hoffman PW, Chernak JM. DNA binding and regulatory effects of transcription factors SP1 and USF at the rat amyloid precursor protein gene promoter. Nucleic Acids Res 23: 2229-2235 (1995).
19. Querfurth HW, Jiang J, Xia W, Selkoe DJ. Enhancer function andnovel DNA binding protein activity in the near upstream βAPP gene promoter. Gene 232: 125-141 (1999).
20. Zawia NH, Basha MR. Environmental risk factors and the developmental basis for Alzheimer's disease. Rev Neurosci 16: 325-337 (2005).
21. Salbaum JM, Weidemann A, Lemaire HG, Masters CL, Beyreuther K. The promoter of Alzheimer's disease amyloid A4 precursor gene. EMBO J 7: 2807-2813 (1988).
22. Basha MR, Wei W, Bakheet SA, Benitez N, Siddiqi HK, Ge YW, et al. The fetal basis of amyloidogenesis: exposure to lead and latent overexpression of amyloid precursor protein and beta-amyloid in the aging brain. J Neurosci 25: 823-829 (2005).
23. Wu J, Basha MR, Brock B, Cox DP, Cardozo-Pelaez F, McPherson CA, et al. Alzheimer's disease (AD)-like pathology in aged monkeys after infantile exposure to environmental metal lead (Pb): evidence for a developmental origin and environmental link for AD. J Neurosci 28: 3-9 (2008).
24. Christensen MA, Zhou W, Qing H, Lehman A, Philipsen S, Song W. Transcriptional regulation of BACE1, the beta-amyloid precursor protein beta-secretase, by Sp1. Mol Cell Biol 24: 865-874 (2004).
25. Cai H, Wang Y, McCarthy D, Wen H, Borchelt DR, Price DL, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4: 233-234 (2001).
26. Heicklen-Klein A, Ginzburg I. Tau promoter confers neuronal specificity and binds Sp1 and AP-2. J Neurochem 75: 1408-1418 (2000).
27. Santpere G, Nieto M, Puig B, Ferrer I. Abnormal Sp1 transcription factor expression in Alzheimer disease and tauopathies. Neurosci Lett 397: 30-34 (2006).
28. Citron B, Dennis J, Zeitlin R, Echeverria V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J Neurosci Res 86: 2499-2504 (2008).
29. Brock B, Basha R, DiPalma K, Anderson A, Harry GJ, Rice DC, et al. Co-localization and distribution of cerebral APP and SP1 and its relationship to amyloidogenesis, J Alzheimers Dis 13: 71-80 (2008).
30. Pollwein P, Masters C, Beyreuther K. The expression of the amyloid precursor protein (APP) is regulated by two GC-elements in the promoter. Nucleic Acids Res 20: 63-68 (1992).
31. Letovsky J, Dynan WS. Measurement of the binding of transcription factor Sp1 to a single GC box recognition sequence. Nucleic Acids Res 17: 2639-2653 (1989).
32. Boelsterli UA. In Mechanistic toxicology, the molecular basis of how chemicals disrupt biological targets. New Yrok: Informa healthcare. pp 8-13 (2009).
33. Marin M, Karis A, Visser P, Grosveld F, Philipsen S. Transcription factor Sp1 is essential for early embryonic development but dispensable for cell growth and differentiation. Cell 89: 619-628 (1997).
34. Abdelrahim M, Baker CH, Abbruzzese JL, Safe S. Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst 98: 855-868 (2006).
35. Konduri SD, Ticku J, Bobustuc GC, Sutphin RM, Colon J, Isley B, et al. Blockade of MGMT expression by O6 benzyl guanine leads to inhibition of pancreatic cancer growth and induction of apoptosis. Clin Cancer Res 15: 6087-6095 (2009).
36. Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 29: 41-51 (2011).
37. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, et al. Dramatic aggregation of Alzheimer Abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem 273: 12817-12826 (1998).
38. Nunomura A, Perry G, Hirai K, Aliev G, Takeda A, Chiba S, et al. Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci 893: 362-364 (1999).
39. Atkins DS, Basha MR, Zawia NH. Intracellular signaling pathways involved in mediating the effects of lead on the transcription factor Sp1. Int J Dev Neurosci 21: 35-44 (2003).
40. Sugihara S, et al. Effect of apolipoprotein E allele epsilon4 on the initial phase of amyloid beta-protein accumulation in the human brain. Am J Pathol 157: 2093-9 (2000).
41. Olkkola KT, Neuvonen PJ. Do gastric contents modify antidotal efficacy of oral activated charcoal?. Br J Clin Pharmacol 18: 663-669 (1984).
42. Igualada C, Moragues F, Pitarch J. Rapid method for the determination of non-steroidal anti-inflammatory drugs in animal tissue by liquid chromatography-mass spectrometry with ion-trapdetector. Anal Chim Acta 586: 432-439 (2007).
43. Yamada T, Sasaki H, Furuya H, Miyata T, Goto I, Sakaki Y. Complementary DNA for the mouse homolog of the human amyloid beta protein precursor. Biochem Biophys Res Commun 149: 665-671 (1987).
44. Manning RW, Reid CM, Lampe RA, Davis LG. Identification inrodents and other species of an mRNA homologous to the human beta-amyloid precursor. Brain Res 427: 293-297 (1988).
45. Snyder S, Ladror U, Wade W, Wang G, Barrett L, Matayoshi E, et al. Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. Biophys 67: 1216-1228 (1994).
46. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, Olm V, et al. Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to P-Amyloid. J Neurosci 23: 29-33 (2003).